Johnny Mahlangu, MD, MMed

Professor in Haematology
University of the Witwatersrand and NHLS

Johnny Mahlangu, MBBCh, MMed
Professor, University of the Witwatersrand and Clinical Haematologist at the Charlotte Maxeke Johannesburg Academic Hospital

Johnny Mahlangu is a Personal Professor in Haematology in the Faculty of Health Sciences of the University of the Witwatersrand and the National Health Laboratory Service and a Consultant Clinical Haematologist at the Charlotte Maxeke Johannesburg Academic Hospital. Johnny received his undergraduate and postgraduate training in science and medicine at the University of the Witwatersrand with haematology specialist and clinical haematology sub-specialist qualifications through the Colleges of Medicine of South Africa. His main area of research is novel therapies in bleeding disorders in which he has served as Principal Investigator for a large number of international multicentre studies. He has published many peer review journal articles and presented more than 500 oral talks and posters at national and international scientific meetings.

Presentation(s):

OC 12.6 - Gene Therapy II
Sunday, July 10, 2022
10:45 AM – 12:00 PM
PB0212 - Collaboration between the World Federation of Hemophilia and National Registries for the Long-Term Follow-up of People with Hemophilia Treated with Gene Therapy
Sunday, July 10, 2022
6:30 PM – 7:30 PM
SS 16.6 - Approaches to Standardisation and Monitoring for Haemophilia Gene Therapy: Consistency, Considerations and Challenges
Monday, July 11, 2022
1:15 PM – 2:30 PM
SS 16.1 - Introduction: Value of Standardisation in the Era of Haemophilia Gene Therapy
Monday, July 11, 2022
1:15 PM – 1:23 PM
OC 40.1 - FRONTIER1: A Phase 1/2 Dose Escalation Study of a Novel Factor VIIIa Mimetic Bispecific Antibody, Mim8, for Evaluation of Safety, Pharmacokinetics, and Efficacy
Monday, July 11, 2022
2:45 PM – 3:00 PM
OC 40.5 - Crimson 1: A Phase 3 study to evaluate the efficacy and safety of subcutaneous marzeptocog alfa (activated) for on-demand treatment of bleed events in subjects with hemophilia A or B, with inhibitors
Monday, July 11, 2022
3:45 PM – 4:00 PM
SSC 13.01 - Welcome and Introduction
Monday, July 11, 2022
4:30 PM – 4:34 PM
OC 50.5 - Mim8 is associated with improved thrombin generation vs. emicizumab in patients with haemophilia A, with and without inhibitors
Tuesday, July 12, 2022
11:45 AM – 12:00 PM
PB1163 - Real-World Unmet Needs of Patients with Haemophilia A/B with or without Inhibitors: Historical Haemophilia Characteristics from Patients Entering a Non-Interventional Study
Tuesday, July 12, 2022
6:30 PM – 7:30 PM
PB1188 - Efficacy and safety of eptacog beta for resolution of spontaneous versus traumatic bleeding episodes in patients with hemophilia A or B with inhibitors
Tuesday, July 12, 2022
6:30 PM – 7:30 PM
OC 70.3 - Unmet Medical Needs in Patient-Reported Outcomes and Sports Activity in People with Haemophilia A/B with or without Inhibitors: Historical Data from Patients Entering a Non-Interventional Study
Wednesday, July 13, 2022
10:45 AM – 11:00 AM